Navigation Links
Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
Date:6/2/2008

responses observed in this trial represent a clinically meaningful outcome for many of these difficult-to-treat AML patients. As a single-agent, single-infusion therapy, Cloretazine(R) (VNP40101M) has the potential to be an important new treatment option for older patients with poor-risk AML."

Alan Kessman, Chief Executive Officer, said, "These interim data continue to demonstrate Cloretazine(R) (VNP40101M)'s potential utility in a patient population which represents an unmet medical need." He added, "It continues to be our plan to file a new drug application with the U.S. Food and Drug Administration in 2008 based on the data from this trial and our previous Phase II trial in elderly patients with AML."

The pivotal Phase II trial started in May 2006 and was conducted in 25 sites in North America and Europe. Enrollment of the primary study was completed in August 2007. The trial remains open at selected sites in order to collect QT/QTc interval data in an electrocardiogram sub-study in accordance with FDA/ICH guidelines.

The study was designed for patients with untreated de novo AML who are age 60 or older and have at least one of the following adverse prognostic factors: age greater or equal to 70, ECOG performance status equal to 2, unfavorable cytogenetics or organ dysfunction. The primary endpoint of the trial is the overall complete response rate measured as either complete remission (CR) or CRp, a complete response with incomplete platelet recovery. Secondary endpoints are progression-free survival, leukemia-free survival, overall survival and the toxicity of Cloretazine(R) (VNP40101M) in this patient population.

Patients receive induction therapy of 600 mg/m2 of Cloretazine(R) (VNP40101M) in a sixty-minute infusion. Second induction is permitted between days 35 and 60 in patients with bone marrow improvement but residual disease. Patients who respond can receive consolidation therapy with a continuous infusion of 400 mg/m2 of cytar
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
2. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
3. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
4. Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting
5. Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
6. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
7. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
8. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
9. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
10. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
11. Tioga Pharmaceuticals Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... STATESVILLE, N.C. , Aug. 27, 2014 ... today its Board of Directors increased its quarterly cash ... from eleven cents per outstanding share, beginning with the ... record at the close of business on September 8, ... Founded in 1906, Kewaunee Scientific Corporation is ...
(Date:8/27/2014)... , Aug. 27, 2014  Columbia Laboratories, Inc. (Nasdaq: ... provider of pharmaceutical development, clinical trial manufacturing, and advanced ... announced that it will participate at the upcoming Rodman ... to be held in New York ... 11:15am on September 9, 2014 at the New York ...
(Date:8/27/2014)... NINGBO, China , Aug. 27, 2014  Amerigen ... Ltd, ("Menovo") today announced they had entered into a ... targeting the United States market. ... will jointly develop products for Amerigen to commercialize in ... be responsible for manufacturing API and finished product whereas ...
Breaking Medicine Technology:Amerigen Pharmaceuticals Limited and the Ningbo Menovo Pharmaceutical Co., Ltd, today announced they had entered into a collaboration agreement regarding the development of generic pharmaceuticals, primarily targeting the United States market 2
... , PLEASANTON, Calif. , July 22 Thoratec Corporation ... therapies to save, support and restore failing hearts, today announced that it ... months of fiscal 2010 on Thursday, July 29 . , ... The company will hold a conference ...
... , MOUNTAIN VIEW, Calif. , July 22 Alexza ... Turner has been appointed to its Board of Directors.  Mr. Turner ... and Ethics Committee. , , ... Turner has over 25 years of experience as a financial manager in ...
Cached Medicine Technology:Thoratec Schedules Second Quarter Conference Call, Webcast 2Alexza Pharmaceuticals Appoints Joseph L. Turner to Its Board of Directors 2Alexza Pharmaceuticals Appoints Joseph L. Turner to Its Board of Directors 3Alexza Pharmaceuticals Appoints Joseph L. Turner to Its Board of Directors 4
(Date:8/27/2014)... August 27, 2014 Parker Waichman LLP, ... rights of victims injured by defective medical devices, reports ... for discovery procedures, specifically Collection and Preservation of Evidence, ... transvaginal mesh devices. (MDL No. 2187, In Re: C.R. ... United States District Court, Southern District or West Virginia; ...
(Date:8/27/2014)... 27, 2014 Ticket Down is a dependable ... Sun Life Stadium in Miami. The Brazilian national soccer ... September 5 at Sun Life Stadium in Miami Gardens, Florida. ... rematch of the World Cup earlier this year when Brazil ... injury. The Brazilian Soccer Federation announced earlier this week that ...
(Date:8/27/2014)... Lee Antimicrobial Solutions LLC (“LAMS”), ... Technology and a Leader in Environmental Disinfection Device ... a device developed for home use available for ... unveiled DHP Technology, a revolutionary means to disinfect ... of bacteria, viruses, microbes and offensive odors. A ...
(Date:8/27/2014)... UK (PRWEB) August 27, 2014 ... through a period of dramatic changes. The country’s ... supervision and administration of medical equipment are far ... economy over the past 30 years. Chinese state ... and Administration of Medical Devices” to try to ...
(Date:8/27/2014)... 27, 2014 When Jagger was 20 years ... his mother; one that he credits as one of the ... had news that she could set him up with a ... disabilities. Jagger took that job, and he has now spent ... past two decades, he also worked in school boards, employment ...
Breaking Medicine News(10 mins):Health News:New Discovery Rules Have Been Put in Place by the Court Overseeing C.R. Bard Transvaginal Mesh Litigation, Parker Waichman LLP Comments 2Health News:New Discovery Rules Have Been Put in Place by the Court Overseeing C.R. Bard Transvaginal Mesh Litigation, Parker Waichman LLP Comments 3Health News:New Discovery Rules Have Been Put in Place by the Court Overseeing C.R. Bard Transvaginal Mesh Litigation, Parker Waichman LLP Comments 4Health News:Brazil vs. Colombia Tickets in Miami, FL: Ticket Down Cuts Ticket Prices on World Cup Rematch of Colombia vs. Brazil at Sun Life Stadium in Miami on Sept. 5th 2Health News:Brazil vs. Colombia Tickets in Miami, FL: Ticket Down Cuts Ticket Prices on World Cup Rematch of Colombia vs. Brazil at Sun Life Stadium in Miami on Sept. 5th 3Health News:A New York Based Company Announces The Release Of An Advanced, Environmentally Friendly Disinfection Technology For In-Home Use 2Health News:A New York Based Company Announces The Release Of An Advanced, Environmentally Friendly Disinfection Technology For In-Home Use 3Health News:Chinese Regulations for Imported Medical Device Registration Discussed by Access China in New Research Report Published at MarketPublishers.com 2Health News:Chinese Regulations for Imported Medical Device Registration Discussed by Access China in New Research Report Published at MarketPublishers.com 3Health News:Fitness on the Go Expands into Liberty Village, City Place and Harbourfront Communities 2Health News:Fitness on the Go Expands into Liberty Village, City Place and Harbourfront Communities 3Health News:Fitness on the Go Expands into Liberty Village, City Place and Harbourfront Communities 4
... Scientists are reporting development and successful initial laboratory tests ... help individuals addicted to heroin abstain from the illicit ... Medicinal Chemistry . Kim D. Janda and colleagues ... than $22 billion in 1996 annually due to medical ...
... 20 (HealthDay News) -- Inherited forms of Alzheimer,s disease ... with memory and thinking develop, according to new research. ... dementia symptoms appear, the disease has severely damaged the ... mental abilities or memories, the study authors noted. ...
... (ROME, 20 July 2011) Bristol-Myers Squibb Company ... study, which included 1,294 antiretroviral (ARV)-experienced patients (336 ... Sweden, that were presented today at the Sixth ... and Prevention (IAS 2011). In a gender-specific ...
... disease, a rare hereditary condition where abnormal fatty deposits collect ... react differently to those in other European countries, according to ... International Journal of Clinical Practice . Researchers from ... different pattern of organ involvement in ill health and death ...
... the University of Liverpool has found that babies admitted to ... are twice as likely to need oxygen therapy and five ... parents do not smoke. The study assessed infants from ... a diagnosis of bronchiolitis. The city has many areas ...
... Reporter , TUESDAY, July 19 (HealthDay News) -- People with ... put themselves at a greater risk of having a heart ... a low dose (typically between 75 and 300 milligrams) is ... disease. Yet as many as 50 percent of patients stop ...
Cached Medicine News:Health News:Study: Inherited Alzheimer's Detectable 20 Years Before Symptom Onset 2Health News:In the real life setting, boosted REYATAZ proves as effective in women living with HIV as men 2Health News:Spanish Fabry disease patients appear to react differently to the rest of Europe 2Health News:Stopping Daily Aspirin Boosts Heart Attack Risk: Study 2Health News:Stopping Daily Aspirin Boosts Heart Attack Risk: Study 3
The S7 Elite is the premium device in ResMeds award-winning S7 series. All S7 devices include an option of integrated humidification....
... The S8 Elite is the premium CPAP device ... generators. The S8 line of flow generators are ... first flow generators to include an option of ... to the device for simplicity and convenience. Premium ...
... freedom and flexibility with the integrated ... battery pack, the system will be ... Also includes an integrated heated humidifier. ... water for one nights use, and ...
... The GoodKnight 420 CPAP System is ... pressure (CPAP) device on the market. It ... patients preserve their lifestyles while complying with ... to 600 sessions of date/time usage data. ...
Medicine Products: